Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanosonics Limited (OtherNNCSF) and Eli Lilly & Co (LLY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nanosonics Limited (NNCSF – Research Report) and Eli Lilly ...
Why Is Eli Lilly and Company (LLY) Among the Best Large-Cap Value Stocks to Buy in 2025?
We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...
Why Are Hedge Funds Bullish on Eli Lilly and Company (NYSE:LLY)?
We recently compiled a list of the 12 Safest Stocks to Buy According to Hedge Funds. In this article, we are going to take a ...
Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement
Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb.
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
Chemistry World6d
J&J’s Intra-Cellular deal could signal more mega-mergers for 2025
The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...
The Motley Fool3d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...
Business Insider2d
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Imagine this: You walk into your doctor and get your yearly flu vaccine and a yearly dose of your weight-loss injection. If Eli Lilly has its way, this may be the future of obesity care.